Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of rechallenge high-dose irinotecan with UGT1A1 genotype in refractory metastatic colorectal cancer
KCT0005303Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan in colorectal cancer (CRC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
irinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on KCT0005303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005303.